Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea
- Author:
Jun Ho YI
1
;
Gyeong-Won LEE
;
Ji Hyun LEE
;
Kwai Han YOO
;
Chul Won JUNG
;
Dae Sik KIM
;
Jeong-Ok LEE
;
Hyeon Seok EOM
;
Ja Min BYUN
;
Youngil KOH
;
Sung Soo YOON
;
Jin Seok KIM
;
Jee Hyun KONG
;
Ho-Young YHIM
;
Deok-Hwan YANG
;
Dok Hyun YOON
;
Do Hyoung LIM
;
Won-Sik LEE
;
Ho-Jin SHIN
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Blood Research 2021;56(4):243-251
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in Western countries but is rare in the East Asian countries. Due to its rarity and the lack of feasible novel agents and laboratory prognostic tools, there are limited data on the clinical outcomes of this disease in Asia. To clarify the current treatment status, we performed a multicenter retrospective analysis of patients with CLL in Korea.
Methods:The medical records of 192 eligible patients between 2008 and 2019 were reviewed for clinical characteristics, treatment courses, and outcomes. The first-line treatment regimens of the patients included in this analysis were as follows: fludarabine/cyclophosphamide/rituximab (FCR) (N=117, 52.7%), obinutuzumab plus chlorambucil (GC) (N=30, 13.5%), and chlorambucil monotherapy (N=24, 10.8%).
Results:The median progression-free survival (PFS) was 55.6 months, and the average 2-year PFS rate was 80.3%. PFS was not significantly different between the patients receiving FCR and those receiving GC; however, chlorambucil treatment was associated with significantly inferior PFS (P ＜0.001). The median overall survival was 136.3 months, and the average 5- and 10-year OS rates were 82.0% and 57.4%, respectively.
Conclusion:This is one of the largest studies involving Korean patients with CLL. Although the patients had been treated with less favored treatment regimens, the outcomes were not different from those reported in Western studies.
